Jake Shortt

4.5k citations

119 papers · 2.3k indexed · h-index 25

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Oncology top 5%

Papers in

Hematology 58
- Acute Myeloid Leukemia Research 26
- Multiple Myeloma Research and Treatments 15
- Chronic Myeloid Leukemia Treatments 11
Genetics 34
- Chronic Lymphocytic Leukemia Research 16
- Myeloproliferative Neoplasms: Diagnosis and Treatment 12

Co-authors: Ricky W. Johnstone James E. Bradner Christopher J. Ott Andrew Spencer Leonie A. Cluse Benjamin P. Martin Johannes Zuber Geoffrey M. Matthews
Journals: Blood (21 papers)HemaSphere (6 papers)British Journal of Haematology (5 papers)Journal of Clinical Oncology (4 papers)European Journal Of Haematology (4 papers)
Partner nations: Australia United States Italy

In The Last Decade

Jake Shortt

110 papers receiving 2.3k citations

Peers

Countries citing papers authored by Jake Shortt

Since Specialization

Citations

This map shows the geographic impact of Jake Shortt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jake Shortt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jake Shortt more than expected).

Fields of papers citing papers by Jake Shortt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jake Shortt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jake Shortt. The network helps show where Jake Shortt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jake Shortt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jake Shortt Line = papers co-authored together Jake Shortt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus Communications Medicine ·Lei Zhang, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, 金德厚, Nadia Warner	2025	5
2	T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Blood Advances ·Eliza A. Hawkes, Jodie Palmer, Richard Khor, Ronald Fabian Güiza Pineda, Melinda Burgess, Soi Cheng Law, Maher K. Gandhi, Geoffrey Chong, Jake Shortt, Rakin Chowdhury, L. Krumholz, Leonid Churilov, Michael MacManus, Charmaine Smith, Fiona E. Scott, Haider Majid Haider Al-Zaidi, Allison Barraclough, Ananda L. Kimm-Drapeau, Andrew M. Scott, Colm Keane	2025	0
3	Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach Internal Medicine Journal ·小百合白木, Anna Sedenu, Felipe Pezoa Dittus, George Grigoriadis, Shaun Fleming, Michael Donald Hank, Pasquale L. Fedele, Michael Löw, Paul Yeh, Michael Gilbertson, C R Jordan, Gareth P. Gregory, Coralie Maurin, D. Pluth, Zane Kaplan, Sanjeev Chunilal, S. Brown, Stephen Opat, Chong Chyn Chua, Jake Shortt	2025	0
4	Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling FEBS Journal ·Matteo Costacurta, Jarrod J. Sandow, Belinda Maher, Olivia Susanto, Stephin J. Vervoort, Jennifer R. Devlin, Daniel J. Garama, Mark R. Condina, Joel R. Steele, Yeqing Sun, Daniel J. Gough, Ricky W. Johnstone, Jake Shortt	2024	4
5	Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies Pathology ·大鹏许, Tapan Kanti Biswas, R. Shamzipour, M. Bakon, Jake Shortt, Pasquale L. Fedele, Michael Gilbertson, Chun Yew Fong, Naranie Shanmuganathan, Beena Kumar, Paul Yeh	2024	2
6	Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial. Journal of Clinical Oncology ·Amer M. Zeidan, Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Guillermo Garcia‐Manero, Jiahui Li, Nathalie Weibel, 太郎宮崎, Shelonitda Rose, Yinzhi Lai, David Valcárcel, Pierre Fenaux, Jake Shortt, Rami S. Komrokji	2024	2
7	A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas Clinical Cancer Research ·Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Samuel Demetouw, Dejan Radeski, Vincent Ribrag, Eva Domingo‐Doménech, Ahmed Sawas, Rawan M. Hammad, Michael Emig, Evenly B. Davidheiser, Fatima Osman A-ltom, Paulien Ravenstijn, Sheena Pinto, Pérola Mathias, Jasmine R. Cloud, Vasyl Kashchyshyn, Steven M. Horwitz	2024	7
8	Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study Blood ·Esther Natalie Olíva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia‐Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, 何宏让, Shien Guo, 邢秋月, Gabriel Neves Cezarette, Joaquim Rosales Rafel, V. Tanturri, Dimana Miteva, Gidron Yori, Nathalie Weibel, Mikkael A. Sekeres, Amer M. Zeidan	2024	2
9	Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS). Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli‐Salazar, Ing Soo Tiong, Chien‐Chin Lin, Jiahui Li, Nathalie Weibel, 太郎宮崎, Jeevan K. Shetty, V. Raj Thaneeghavl, Carlo Finelli, Thomas Cluzeau, Matteo Giovanni Della Porta	2023	0
10	A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma Clinical Epigenetics ·Jake Shortt, Peter Galettis, Chan Y. Cheah, Joanne E. Davis, Mandy Ludford‐Menting, Emma Link, Jennifer Martin, Rachel Koldej, David Ritchie	2023	3
11	A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma (AMaRC 01‐16) British Journal of Haematology ·Andrew Spencer, Anna Kalff, Jake Shortt, Hang Quach, Craig T. Wallington‐Beddoe, John Reynolds, Patricia Walker, Simon J. Harrison, Rana Noori Majeed, Cameron Wellard	2023	2
12	Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care Journal of the National Comprehensive Cancer Network ·Ernestine Kotthoff‐Burrell, Tomáš Frejlich, Stephen Opat, Jake Shortt, Peter Poon	2023	4
13	High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma European Journal Of Haematology ·Anna Sedenu, W.D. Gassel, محمدحسین حسنی, BantwalP Baliga, Eldho Paul, Stephen Opat, Claire Dendle, Jake Shortt	2023	4
14	Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance Internal Medicine Journal ·Greg Hapgood, Maya Latimer, Sze Ting Lee, Bryone J. Kuss, Stephen Lade, Joshua W.D. Tobin, Duncan Purtill, Belinda A. Campbell, H. Miles Prince, Eliza A. Hawkes, Jake Shortt, Dejan Radeski	2021	0
15	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy Leukemia & lymphoma ·Taslima Akter, Lackson Kashobwe, Xuan Guo, Gareth P. Gregory, Constantine S. Tam, Hang Quach, Erin Dyer Olson, Robin Filshie, Matthew Ku, Anna Sedenu, Jake Shortt, Stephen Opat	2020	8
16	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members Molecular Cancer Therapeutics ·Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort, Leonie A. Cluse, Benjamin P. Martin, Gareth P. Gregory, Marcus Lefebure, Eva Vidacs, Richard W. Tothill, James E. Bradner, Jake Shortt, Ricky W. Johnstone	2016	50
17	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Cancer Discovery ·Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J. George, Jake Shortt, Megan J. Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O’Brien, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Richard B. Pearson	2015	91
18	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia Cancer Research ·Adele Baker, Gareth P. Gregory, Inge Verbrugge, Lev M. Kats, Ye-Fang CHEN, Eva Vidacs, Erwin M. Lee, Richard B. Lock, Johannes Zuber, Jake Shortt, Ricky W. Johnstone	2015	83
19	An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors Cancer Research ·Alison C. West, Stephen R. Mattarollo, Jake Shortt, Leonie A. Cluse, Ailsa J. Christiansen, Mark J. Smyth, Ricky W. Johnstone	2013	117
20	The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence Cancer Discovery ·Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone, Grant A. McArthur	2012	52

About Jake Shortt

Jake Shortt is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Immunology, having authored 119 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (29 papers), Acute Myeloid Leukemia Research (26 papers), Protein Degradation and Inhibitors (24 papers), Chronic Lymphocytic Leukemia Research (16 papers), Multiple Myeloma Research and Treatments (15 papers), Histone Deacetylase Inhibitors Research (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers) and Chronic Myeloid Leukemia Treatments (11 papers). The work is most often cited by research in Hematology (665 citations), Oncology (756 citations), Genetics (270 citations), Immunology (493 citations) and Molecular Biology (1.3k citations). Jake Shortt has collaborated with scholars based in Australia, United States and Italy. Frequent co-authors include Ricky W. Johnstone, James E. Bradner, Christopher J. Ott, Andrew Spencer, Leonie A. Cluse, Benjamin P. Martin, Johannes Zuber, Geoffrey M. Matthews, P. Leif Bergsagel and Marta Chesi. Their work appears in journals such as Blood, HemaSphere, British Journal of Haematology, Journal of Clinical Oncology and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact